oxerutins: clinical use

Prescribing considerations

• Confirm that oedema is attributable to chronic venous insufficiency rather than cardiac, renal, hepatic, thrombotic or other disease.
• Safety and efficacy have not been established in people under 18.
• Review persistent or worsening pain and swelling rather than continuing symptomatic treatment without reassessment.

Contraindications and cautions

• Hypersensitivity to oxerutins or any capsule excipient.
• Do not use to treat lower-limb oedema caused by cardiac, renal or hepatic disease.

Monitoring

• No routine laboratory monitoring is specified.
• Monitor symptom response and reassess the diagnosis if swelling fails to improve or worsens.
• Ask about gastrointestinal, skin and hypersensitivity reactions.

Clinical pharmacology

Oxerutins is a standardised mixture of hydroxyethylrutosides. It acts principally on microvascular endothelium, reducing capillary permeability. Following oral absorption, it undergoes hepatic O-glucuronidation and metabolites are eliminated through biliary and renal routes.

Formulation and product differences

• The selected product is an oral capsule that must be swallowed whole.
• The capsule contains gelatin and should be protected from moisture.